REG - Physiomics PLC - Board Changes

PhysiomicsAnnouncement

23/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220223:nRSW4834Ca&default-theme=true

RNS Number : 4834C  Physiomics PLC  23 February 2022

23 February 2022

Physiomics plc

("Physiomics" or "the Company")

 

Board Changes

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions, announces that Dr Paul Harper is standing down from the
role of Non-Executive Chairman and as a Director of the Company with immediate
effect.  Dr Harper has served the Company since 2004 as Non-Executive
Director, and since 2007 as Chairman, and the Board would like to express its
thanks for his contribution and long service.

Dr Jim Millen will retain the role of CEO of Physiomics and additionally
assume the role of Executive Chairman, but no other board changes will be made
immediately.  The Company is seeking to appoint at least one independent
Non-Executive Director as soon as possible and a further announcement in this
regard will be made in due course.

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0)20 3764 2341

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of
the European Union (Withdrawal) Act 2018, as amended.

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

For more information please visit:

 

www.physiomics.co.uk (http://www.physiomics.co.uk)

www.twitter.com/Physiomics (http://www.twitter.com/Physiomics)

www.linkedin.com/company/physiomics-plc/
(http://www.linkedin.com/company/physiomics-plc/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUQAPUPPGMP